Table 1

 Characteristics of the cohort with psoriatic arthritis

DIP, distal interphalengeal; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IQR, interquartile range; PASI, Psoriasis Area and Severity Index; MH, medical history; PsA, psoriatic arthritis.
*Involved joints refer to tender, swollen or damaged joints.
Characteristics of patients with PsA (n = 480)
    Female gender, n (%)275 (57)
    Plaque psoriasis, n (%)393 (82)
    Type I psoriasis (age at onset ⩽40 years), n (%)354 (74)
    Type II psoriasis (age at onset >40 years), n (%)123 (26)
    Median (IQR) age at onset of psoriasis (years)26 (15–42.5)
    Median (IQR) age at onset of arthritis (years)36.5 (26–49)
Family history of
    Psoriasis, n (%)236 (49)
    PsA, n (%)34 (7)
    Nail involvement, n (%)391 (81)
    Presence of rheumatoid factor, n (%)81 (17)
    Ever used DMARD, n (%)389 (81)
    MH of dysentery, n (%)20 (4)
    MH conjunctivitis, n (%)156 (33)
    MH uveitis, n (%)23 (5)
    MH recurrent mouth ulcers, n (%)157 (33)
    MH of sexually transmitted disease, n (%)12 (3)
    Median (IQR) PASI6 (2.5–11.2)
    Median (IQR) HAQ1.25 (0.25–1.875)
    Median (IQR) duration of psoriasis (years)19 (9–33)
    Median (IQR) duration of arthritis (years)10 (5–19)
Onset
    Psoriasis (>1 year) before arthritis, n (%)304 (63)
    Arthritis (>1 year) before psoriasis, n (%)72 (15)
    Psoriasis and arthritis at the same time (±1 year), n (%)104 (22)
Involved joint *
    Whole cohort, median (IQR)10 (4.5–21)
    Presence of DIP involvement, n (%)310 (65)
    Mono-involved joints, n (%)22 (5)
    Oligo-involved joints (⩽4 joints), n (%)98 (20)
    Poly-involved joints (⩾5 joints), n (%)360 (75)
Tender joint count
    Whole cohort, median (IQR)2 (0–6)
Swollen joint count
    Whole cohort, median (IQR)1 (0–4)
Damaged joints
    Whole cohort, median (IQR)6 (2–15)
    DIP damaged, n (%)257 (54)
    Mono-damaged, n (%)36 (8)
    Oligo-damaged (⩽ 4 joints), n (%)132 (28)
    Poly-damaged joints (⩾5 joints), n (%)272 (57)